Zurcher Kantonalbank (Zurich Cantonalbank) Bio Xcel Therapeutics, Inc. Transaction History
Zurcher Kantonalbank (Zurich Cantonalbank)
- $32.8 Billion
- Q3 2024
A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Bio Xcel Therapeutics, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 6,028 shares of BTAI stock, worth $2,049. This represents 0.0% of its overall portfolio holdings.
Number of Shares
6,028
Previous 6,028
-0.0%
Holding current value
$2,049
Previous $3,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding BTAI
# of Institutions
52Shares Held
3.12MCall Options Held
22.2KPut Options Held
40.2K-
Vanguard Group Inc Valley Forge, PA1.2MShares$408,4680.0% of portfolio
-
Black Rock Inc. New York, NY441KShares$149,8320.0% of portfolio
-
Geode Capital Management, LLC Boston, MA298KShares$101,3340.0% of portfolio
-
Wells Fargo & Company San Francisco, CA185KShares$62,9190.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny130KShares$44,1550.0% of portfolio
About BioXcel Therapeutics, Inc.
- Ticker BTAI
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 28,022,500
- Market Cap $9.53M
- Description
- BioXcel Therapeutics, Inc. is a commercial-stage biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and prop...